Ali Rizvi to Paclitaxel
This is a "connection" page, showing publications Ali Rizvi has written about Paclitaxel.
Connection Strength
0.314
-
Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Am Heart J. 2013 Dec; 166(6):1035-42.
Score: 0.109
-
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2013 Sep; 6(9):914-22.
Score: 0.107
-
Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention. 2012 May 15; 8(1):87-93.
Score: 0.098